Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma

Palomba,Grazia; Cossu,Antonio; Paliogiannis,Panagiotis; Pazzola,Antonio; Baldino,Giovanni; Scartozzi,Mario; Ionta,Maria  Teresa; Ortu,Salvatore; Capelli,Francesca; Lanzillo,Annamaria; Sedda,Tito; Sanna,Giovanni; Barca,Michela; Virdis,Luciano; Budroni,Mario; Palmieri,Giuseppe

doi:10.3892/ol.2016.4798

Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma

Authors:
- Grazia Palomba
- Antonio Cossu
- Panagiotis Paliogiannis
- Antonio Pazzola
- Giovanni Baldino
- Mario Scartozzi
- Maria Teresa Ionta
- Salvatore Ortu
- Francesca Capelli
- Annamaria Lanzillo
- Tito Sedda
- Giovanni Sanna
- Michela Barca
- Luciano Virdis
- Mario Budroni
- Giuseppe Palmieri
View Affiliations

Affiliations: Institute of Biomolecular Chemistry, CNR, 07100 Sassari, Italy, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, 07100 Sassari, Italy, Oncology Unit, Local Health Unit (ASL1), 07100 Sassari, Italy, Oncology Unit, Civil Hospital, 07041 Alghero, Italy, Department of Medical Oncology, University of Cagliari, 09042 Cagliari, Italy, Oncology Unit, Local Health Unit (ASL2), 07026 Olbia, Italy, Oncology Unit, Zonchello Hospital, 08100 Nuoro, Italy, Oncology Unit, Businco Hospital, 09121 Cagliari, Italy, Oncology Unit, Local Health Unit (ASL), 09170 Oristano, Italy, Department of Medical Oncology, Hospital University (AOU), 07100 Sassari, Italy, Oncology Unit, Local Health Unit (ASL4), 08045 Lanusei, Italy, Oncology Unit, Local Health Unit (ASL7), 09013 Carbonia‑Iglesias, Italy
Published online on: June 29, 2016 https://doi.org/10.3892/ol.2016.4798
Pages: 1415-1421
Copyright: © Palomba et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The presence of mutations in the KRAS gene is a predictor of a poor clinical response to EGFR-targeted agents in patients affected by colorectal cancer (CRC), but its significance as a global prognostic factor remains unclear. The aim of the present study was to evaluate the impact of the KRAS mutational status on time to first metastasis (TTM) and overall survival (OS) in a cohort of Sardinian CRC patients. A total of 551 patients with metastatic CRC at the time of enrolment were included. Clinical and pathological features of the disease, including follow‑up information, were obtained from medical records and cancer registry data. For mutational analysis formalin‑fixed paraffin‑embedded tissue samples were processed using a standard protocol. The coding sequence and splice junctions of exons 2 and 3 of the KRAS gene were screened for mutations by direct automated sequencing. Overall, 186 KRAS mutations were detected in 183/551 (33%) patients: 125 (67%) were located in codon 12, 36 (19%) in codon 13, and 18 (10%) in codon 61. The remaining mutations (7; 4%) were detected in uncommonly‑affected codons. No significant correlation between KRAS mutations and gender, age, anatomical location and stage of the disease at the time of diagnosis was identified. Furthermore, no prognostic value of KRAS mutations was found considering either TTM or OS. When patients were stratified by KRAS mutational status and gender, males were significantly associated with a longer TTM. The results of the present study indicate that KRAS mutation correlated with a slower metastatic progression in males with CRC from Sardinia, irrespective of the age at diagnosis and the codon of the mutation.

View Figures

View References

1	Palmieri G, Paliogiannis P, Scognamillo F, Budroni M, Cesaraccio R, Pulighe F, Tanda F, Trignano M and Cossu A: Colorectal cancer epidemiology in an area with a spontaneous screening program. Acta Med Mediterr. 29:231–234. 2013.
2	Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, et al: Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 116:544–573. 2010. View Article : Google Scholar : PubMed/NCBI
3	Paliogiannis P, Cossu A, Tanda F, Palmieri G and Palomba G: KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. Oncol Lett. 8:1422–1426. 2014.PubMed/NCBI
4	Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW and Burgess AW: Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res. 284:31–53. 2003. View Article : Google Scholar : PubMed/NCBI
5	Yuan ZX, Wang XY, Qin QY, Chen DF, Zhong QH, Wang L and Wang JP: The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: A meta-analysis. PLoS One. 8:e659952013. View Article : Google Scholar : PubMed/NCBI
6	Malumbres M and Barbacid M: RAS oncogenes: The first 30 years. Nat Rev Cancer. 3:459–465. 2003. View Article : Google Scholar : PubMed/NCBI
7	Heinemann V, Stintzing S, Kirchner T, Boeck S and Jung A: Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev. 35:262–271. 2009. View Article : Google Scholar : PubMed/NCBI
8	Bardelli A and Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 28:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
9	Lin AY, Buckley NS, Lu AT, Kouzminova NB and Salpeter SR: Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: A systematic review and meta-analysis. Clin Colorectal Cancer. 10:63–69. 2011. View Article : Google Scholar : PubMed/NCBI
10	Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, et al: Kirsten ras mutations in patients with colorectal cancer: The ‘RASCAL II’ study. Br J Cancer. 85:692–696. 2001. View Article : Google Scholar : PubMed/NCBI
11	Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, et al: Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 18:4753–4763. 2012. View Article : Google Scholar : PubMed/NCBI
12	Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD and Newcomb PA: KRAS-mutation status in relation to colorectal cancer survival: The joint impact of correlated tumour markers. Br J Cancer. 108:1757–1764. 2013. View Article : Google Scholar : PubMed/NCBI
13	Palomba G, Colombino M, Contu A, Massidda B, Baldino G, Pazzola A, Ionta M, Capelli F, Trova V, Sedda T, et al: Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: Clues from Sardinia. J Transl Med. 10:1782012. View Article : Google Scholar : PubMed/NCBI
14	Schubbert S, Shannon K and Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 7:295–308. 2007. View Article : Google Scholar : PubMed/NCBI
15	Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J and Kim J: Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 13:12153–12168. 2012. View Article : Google Scholar : PubMed/NCBI
16	de Macedo MP, de Lima LG, Begnami MD, de Melo FM, Andrade LD, Lisboa BC, Soares LM, Soares FA, Carraro DM and da Cunha IW: KRAS insertions in colorectal cancer: What do we know about unusual KRAS mutations? Exp Mol Pathol. 96:257–260. 2014. View Article : Google Scholar : PubMed/NCBI
17	Tanaka M, Omura K, Watanabe Y, Oda Y and Nakanishi I: Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol. 57:57–64. 1994. View Article : Google Scholar : PubMed/NCBI
18	Morrin M, Kelly M, Barrett N and Delaney P: Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut. 35:1627–1631. 1994. View Article : Google Scholar : PubMed/NCBI
19	Bennett MA, Kay EW, Mulcahy H, O'flaherty L, O'donoghue DP, Leader M and Croke DT: Ras and p53 in the prediction of survival in Dukes' stage B colorectal carcinoma. Clin Mol Pathol. 48:M310–M315. 1995. View Article : Google Scholar : PubMed/NCBI
20	Lee JC, Wang ST, Lai MD, Lin YJ and Yang HB: K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res. 16:3839–3844. 1996.PubMed/NCBI
21	Pricolo VE, Finkelstein SD, Wu TT, Keller G, Bakker A, Swalsky PA and Bland KI: Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg. 171:41–46. 1996. View Article : Google Scholar : PubMed/NCBI
22	Kressner U, Bjørheim J, Westring S, Wahlberg SS, Påhlman L, Glimelius B, Lindmark G, Lindblom A and Børresen-Dale AL: Ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer. 34:518–521. 1998. View Article : Google Scholar : PubMed/NCBI
23	Andreyev HJ, Norman AR, Cunningham D, Oates JR and Clarke PA: Kirsten ras mutations in patients with colorectal cancer: The multicenter ‘RASCAL’ study. J Natl Cancer Inst. 90:675–684. 1998. View Article : Google Scholar : PubMed/NCBI
24	Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28:466–474. 2010. View Article : Google Scholar : PubMed/NCBI
25	Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M and Slattery ML: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prev. 9:1193–1197. 2000.PubMed/NCBI
26	Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL and Fuchs CS: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 58:90–96. 2009. View Article : Google Scholar : PubMed/NCBI
27	Zlobec I, Kovac M, Erzberger P, Molinari F, Bihl MP, Rufle A, Foerster A, Frattini M, Terracciano L, Heinimann K and Lugli A: Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer. 127:2569–2575. 2010. View Article : Google Scholar : PubMed/NCBI
28	Winder T, Mündlein A, Rhomberg S, Dirschmid K, Hartmann BL, Knauer M, Drexel H, Wenzl E, De Vries A and Lang A: Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep. 21:1283–1287. 2009. View Article : Google Scholar : PubMed/NCBI
29	Bazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G, et al: Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: Results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol. 16(Suppl 4): iv50–iv55. 2005.PubMed/NCBI
30	Ren J, Li G, Ge J, Li X and Zhao Y: Is K-ras gene mutation a prognostic factor for colorectal cancer: A systematic review and meta-analysis. Dis Colon Rectum. 55:913–923. 2012. View Article : Google Scholar : PubMed/NCBI
31	Troungos C, Valavanis C, Kapranos N and Kittas C: K-ras mutation in Greek patients with poorly and moderately differenciated tumours of the lower intestinal tract. Anticancer Res. 17:1399–1404. 1997.PubMed/NCBI
32	Cerottini JP, Caplin S, Saraga E, Givel JC and Benhattar J: The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg. 175:198–202. 1998. View Article : Google Scholar : PubMed/NCBI